ActiTrexx Completes Final Patient Treatment in GvHD Therapy Study

ActiTrexx GmbH has concluded the treatment of the last patient in its Phase Ib/II study using Actileucel, an innovative regulatory T cell therapy against Graft-versus-Host Disease (GvHD). This therapy is the first to use T cells from unmatched third-party donors. The Mainz-based company aims to address the serious complications of GvHD that arise post stem cell transplantation.

Actileucel is developed within 24 hours through a proprietary process. The study was conducted across four German sites, involving ten patients with haematological malignancies. Initial follow-up is assessing the safety and efficacy of the treatment, with results expected to be shared in a peer-reviewed journal.

Led by Prof. Dr. Andrea Tüttenberg, ActiTrexx, a clinical-stage biotech firm, focuses on innovative therapies for autoimmune diseases. The company’s strategy capitalizes on the Nobel Prize-winning research on regulatory T cells, underscoring their critical role in immune regulation.